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BACKGROUND: Recently established genome editing technologies will open new avenues for biological research and development. Human 
genome editing is a powerful tool which offers great 
scientific and therapeutic potential.
CONTENT: Genome editing using the clustered regularly 
interspaced short palindromic repeats (CRISPR)/CRISPR-
associated protein 9 (Cas9) technology is revolutionizing 
the gene function studies and possibly will give rise to an 
entirely new degree of therapeutics for a large range of 
diseases. Prompt advances in the CRISPR/Cas9 technology, 
as well as delivery modalities for gene therapy applications, 
are dismissing the barriers to the clinical translation of this 
Abstract
R E V I E W  A R T I C L E
technology. Many studies conducted showed promising 
results, but as current available technologies for evaluating 
off-target gene modification, several elements must be 
addressed to validate the safety of the CRISPR/Cas9 
platform for clinical application, as the ethical implication 
as well. 
SUMMARY: The CRISPR/Cas9 system is a powerful 
genome editing technology with the potential to create a 
variety of novel therapeutics for a range of diseases, many 
of which are currently untreatable.
KEYWORDS: genome editing, CRISPR-Cas, guideRNA, 
DSB,  ZFNs,  TALEN
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Introduction
In the 1970s, a new horizon in Biology era was started. 
Through the recombinant DNA development, molecular 
biologist made it possible to study genes and manipulate 
DNA molecules for the 1st time, harness them to developed 
more advanced medicine and biotechnology. Researchers 
now cannot separate the study of DNA from genome 
context. DNA sequences can be directly edited to modulate 
their function in endogenous context virtually, and this can 
be applied to any organism of choice, allowing them to 
elucidate the functional organization of the genome at the 
systems level and also identify causal genetic variations.(1)
 Eukaryotic genomes contain billions of DNA 
bases and are not prone to manipulate. One of the 
breakthroughs in genome manipulation is the development 
of gene targeting by homologous recombination (HR) that 
integrates exogenous repair templates that contain sequence 
homology to the donor site.(2) HR-mediated targeting has 
facilitated the generation of knocking and knockout animal 
models via manipulation of germline-competent stem 
cells, dramatically advancing numerous areas of biological 
research.
 Genome engineering generally refers to the process, 
the contexts (e.g., epigenetic marks), or the outputs (e.g., 
transcripts) of targeted modifications of genomes. Efficient 
and easy to do in eukaryotic and specific mammalian cells, 
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this ability holds enormous, not only promise but also 
challenges to transform basic science, biotechnology and 
medicine. Therefore, a series of programmable nuclease-
based genome editing have been developed to enable this 
genome engineering, particularly in mammalian species. 
CRISPR-associated protein 9 (Cas9), an RNA-guided 
endonuclease from microbial adaptive immune system 
clustered regularly interspaced short palindromic repeats 
(CRISPR), is the most rapidly developing among the current 
generation of genome editing technologies, which can be 
easily virtually targeted to any genomic location of choice 
by a short RNA guide.(1)
 Studies by Haber and Jasin led to the realization 
that targeted DNA double-strand break (DSB) could 
largely stimulate genome editing through HR-mediated 
recombination events.(3-8) Subsequently, Carroll and 
Chandrasegaran showed the potential of designer nucleases 
based on zinc finger proteins for efficient, locus-specific 
HR.(7,8) Moreover, it was presented in the absence of 
an exogenous homology repair template which localized 
DSBs can cause insertions or deletion mutations (indels) 
via the error-prone nonhomologous end-joining (NHEJ) 
repair pathway.(9) These early genome editing studies 
built DSB-induced HR and NHEJ as powerful pathways 
for the versatile and precise modification of eukaryotic 
genomes. There are four major classes of customizable 
DNA-binding proteins that have been engineered so far. 
To achieve effective genome editing via introduction of 
site-specific DNA DSBs, such as meganucleases derived 
from microbial mobile genetic elements (10) zinc-finger 
nucleases (ZFNs) based on eukaryotic transcription factors 
(11,12), transcription activator-like effectors (TALEs) from 
Xanthomonas bacteria (13-16) and very recently the RNA-
guided DNA endonuclease Cas9 from the type II bacterial 
adaptive immune system CRISPR (17,18).
 New modes of recognition with simplification of 
custom nucleases development were needed to answer 
the challenges associated with the engineering of modular 
DNA-binding proteins. A short guide RNA, via Watson-
Crick base pairing recognizing the target DNA and then 
targeted the CRISPR nuclease Cas9.  Within these CRISPR 
RNAs, the guide sequence typically corresponds to phage 
sequences, forming the natural mechanism for CRISPR 
antiviral defense, yet can be simply replaced by a sequence 
of interest to retarget the Cas9 nuclease. More achievement 
gained at an unprecedented scale by introducing a battery 
of short guide RNAs rather than a library of large, bulky 
proteins to multiplexed targeting by Cas9. The high 
efficiency of Cas9 as a site-specific targeting nuclease, plus 
CRISPR-Cas Immune System in Procaryotes
It was conceived after a yogurt company in 2007 identified 
an unexpected defense mechanism that its bacteria use to 
fight off viruses. Then the birth announced in 2012 followed 
by rapid and crucial progress within a year.  Now, it has 
matured into a molecular marvel, and much of the world, 
not just biologists, are taking notice of the genome-editing 
method  CRISPR,  Science’s  2015  Breakthrough  of  the 
Year.(20) The battle for survival between bacteria and the 
viruses which infect them (phages) has led to the evolution 
of many bacterial defense systems and phage-encoded 
antagonists of these systems. CRISPR and the Cas genes 
comprise an adaptive immune system that is one of the most 
widespread means by which bacteria defend themselves 
against phages.(21-24)
 CRISPR-Cas systems are classified into three major 
types, namely type I, type II and type III, and also into 12 
subtypes, given their genetic content and structural and 
functional differences.(25,26) These types and subtypes 
core defining features based on the Cas genes and the 
proteins they encode. The immensely varies genetics and 
functions illustrate how diverse the biochemical functions 
they can carry throughout CRISPR-mediated immunity 
in each different steps. The RNA recognition motif is 
the possibility of highly multiplexed modifications make a 
high possibility for a broad range of biological applications 
across basic research to biotechnology and medicine. 
 The era of straightforward genome editing boosts 
ethical questions that will need to be addressed by scientists 
and society widely. How can we utilize this powerful tool in 
such a way as to assure maximum benefit while minimizing 
risks?(19) The identification of the CRISPR-Cas9 technology 
underscores the way in which many inventions having 
advanced molecular biology and medicine emerged, through 
basic research on natural mechanisms of DNA replication, 
repair, and defense against viruses. In many cases, key 
methodologies turned up from the study of bacteria. The 
CRISPR-Cas9 technology originated through a similar 
process, once the mechanism underlying how CRISPR-
Cas9 system works was understood, it could be harnessed 
for applications in molecular biology and genetics that were 
not previously envisioned.(19) This review will give us the 
insight of how far this genome-editing technology which 
is applied as a new hope in treating currently “impossible” 
illness.
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 CRISPR systems are adaptable immune mechanisms 
used by many bacteria to protect themselves from foreign 
nucleic acids, such as viruses or plasmids.(30,45-47) Type 
II CRISPR systems incorporate sequences from invading 
DNA between CRISPR repeat sequences encoded as arrays 
in the bacterial host genome. Transcripts of the CRISPR 
repeat arrays are processed into crRNA, each harboring 
a variable sequence transcribed from the invading DNA, 
or known as the “protospacer” sequence, and part of the 
CRISPR repeat. Each crRNA hybridizes with a second 
RNA, which is known as the transactivating crRNA 
(tracrRNA) (48), and these two RNAs complex with the 
Cas9 nuclease (43). Only when PAMs located adjacent to 
the protospacer-encoded portion of the crRNA, Cas9 will be 
directed to cleave complementary target-DNA sequences. 
The type II CRISPR system from Streptococcus pyogenes 
has been adjusted for inducing sequence-specific DSBs 
and targeted genome editing.(43) In simple words, genome 
editing could be performed if the Cas9 nuclease and a guide 
RNA, amount to a fusion of a crRNA and a fixed tracrRNA 
can be incorporated into and/or expressed in cells or an 
organism.(49)
 Targeted genome editing using engineered nucleases 
has rapidly moved from being a niche technology to a 
mainstream method used by many biological researchers. 
This widespread adoption has been greatly fueled by the 
emergence of CRISPR technology, a new approach for 
generating RNA-guided nucleases, for example Cas9. 
Genome editing mediated by these nucleases has been 
used to quickly, easily and efficiently modify endogenous 
genes in a broad variety of biomedically relevant cell types 
and in organisms that have traditionally been challenging 
widely spread in many Cas proteins, and most of the Cas 
families of proteins carry functional domains which interact 
with nucleic acids, such as DNA binding, RNA binding, 
helicase and nuclease motifs.(25-29) Cas 1 and Cas 2 
occurs genetically across types and subtypes, while Cas 
3, 9 and 10 respectively designated as the signature genes 
for type I, II and III. Type II system phylogenetically has 
only been identified in bacteria, yet there is a bias for type 
I systems in bacteria and type III systems in archaea and 
hyperthermophiles.(30)
 Adaptive immunity occurs in three stages [for recent 
reviews, (30-32)]. Those stages are: (i) insertion of a short 
sequence of the invading DNA into the CRISPR array as 
a spacer sequence; (ii) transcription of precursor CRISPR 
RNA (pre-crRNA) which goes through maturation to yield 
individual crRNAs, each composed of a repeat portion 
and an invader-targeting spacer portion; also (iii) crRNA-
directed cleavage of foreign nucleic acid because of Cas 
proteins at sites complementary to crRNA spacer sequence 
(Figure 1). In this overall theme, three CRISPR-Cas system 
types (I, II and III) use  distinct  molecular  mechanisms 
to  achieve nucleic acid recognition and cleavage.(22,25) 
The protospacer adjacent motif (PAM), or also known as 
a short sequence motif adjacent to the crRNA-targeted 
sequence on the invading DNA, has significant role in the 
stages of adaptation and interference in type I and type II 
systems.(33-36) The type I and type III systems use a large 
complex of Cas proteins for crRNA-guided targeting.(37-
42) However, the type II system requires merely a single 
protein for RNA-guided DNA recognition and cleavage, 
a property that proved to be highly useful for genome 
engineering applications.(19,43,44)
Figure 1. The Three Stages of CRISPR Immunity.(30) 
(Adapted with permission from Cell Press). 
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to manipulate genetically. The potency of these systems to 
perform targeted, hugely efficient alterations of genome 
sequence and gene expression will certainly transform 
biological research and spur the development of novel 
molecular therapeutics for human disease.(49)
Genome-Editing Technologies
We need to understand the complex and dynamic functions 
of multiple genes network to able precisely manipulate 
genes, involving genes pathways which drive many essential 
cellular activities, including genome replication and repair, 
cell division and differentiation, also disease progression 
and inheritance.(50) The science of genetics relies heavily 
on the analysis of mutations and the phenotypes they 
cause. Many geneticists explore targetable nucleases to 
particular genes of interest which provide the ability for 
any direct mutations and precise sequence changes. This 
will continually create excitation to improve more new 
technologies.(51-53) The development of tools to generate 
DNA breaks, activate (54), repress or label genomic loci 
(55,56) and  remodel  chromatin (57) in a controlled, 
targeted manner will hugely aid the studies of a broad range 
of biological issues, including gene and genomic functions. 
The ability to specifically modify the genome also holds 
significant promise for targeted gene therapies.(58)
 Gene therapy has historically been defined as insertion 
of new genes into human cells. Current technologies in this 
field facilitate a new paradigm to achieve a therapeutic 
effect by precisely manipulating one or more sequences of 
the human genome, include correcting gene mutations that 
cause disease, adding genes to specific sites in the genome 
for therapeutic purpose, or removing destructive genes or 
genome sequences.(59) One way to explore the function 
of genes is to agitate their expression through repression. 
The dominant tool for programmed knockdown of mRNAs 
is RNA interference (RNAi).(60) Yet, RNAi has pervasive 
problems with off-target effects, which can be especially 
confounding in the context of large-scale screens.(61-63) 
RNAi is mediated by cytoplasmic argonaute proteins so that 
gene silencing could be performed by depletion of cytosolic 
mRNA targets.(64) 
 The discovery of using targeted DNA DSBs to 
stimulate the endogenous cellular repair machinery soon 
become the foundation to gene editing. Breaks in the DNA 
are typically repaired through one of two major pathways, 
which are homology-directed repair (HDR) or NHEJ.(65) Figure 2. Repair of a DBS .(74) (Adapted with permission from Annual Reviews).
HDR  depends  on  strand  invasion of the broken end 
into a homologous sequence and subsequent repair of the 
break in a template-dependent manner.(66) Maria Jasin lab 
reported an original work about stimulating the efficiency of 
gene targeting through HR in mammalian cells via a DSB 
introducing at the target site.(6,67,68) Alternatively, NHEJ 
functions to repair DSBs without a template through direct 
religation of the cleaved ends.(69) This repair pathway 
is error-prone and often leads to indels at breaking site. 
Stimulation of NHEJ by site-specific DSBs has been used 
to disrupt target genes in a huge variation of cell types and 
organisms by taking some benefit of these indels to alter the 
reading frame of a gene.(9,70-73) Armed with the capability 
to harness the cell’s endogenous DNA repair machinery, it is 
now feasible to engineer a broad variety of genomic changes 
in a site-specific manner.(59,74) The repairing process a 
DSB is shown by Figure 2. 
 A concerted effort by various academic and industrial 
groups to develop programmable DNA recognition and 
cleavage technologies was inspired by the demonstration 
of a site-specific DSB could be utilized to attain gene 
interruption and gene targeting in otherwise refractory cells.
 Over   the   last  15   years,   this   effort  has   yielded 
several designer endonuclease platforms, including 
meganucleases (75,76), ZFNs (77,78), TALENs (79,80) 
and CRISPR (19,81) (Figure 3). ZFNs consist of DNA-
binding modules derived from natural transcription factors 
which are linked to the nuclease domain of the Type IIS 
restriction enzyme, FokI.(18,19) To cut the DNA, two 
ZFN molecules are required in a single site target, then 
the nuclease domain will be  dimerized.  TALENs  employ 
DNA-binding  modules  from bacterial  TALEs  linked 
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to  the  same FokI cleavage domain.(20) The CRISPR/
Cas RNA-guided nucleases (RGNs) count on base-pairing 
between a guide RNA and the DNA target for recognition 
and on a multifunctional Cas9 protein for cleavage.(21, 22) 
We will discuss all of these types of reagents in detail after 
this. There are members of another class which have long 
recognition sites (15–30 bp) but do not have distinct binding 
and cleavage domains known as the homing endonucleases 
(HE) or meganucleases.(Figure4).
 Once an endonuclease is designed to cut a given 
target sequence, it must be delivered to the therapeutically 
relevant cell. While there are few limitations on delivery 
to cultured cell lines, delivery to primary cells ex vivo 
(such as hematopoietic stem cells and T-cells) and in vivo 
delivery (such as to the liver) have many of the same 
limitations as other classical “gene therapy” approaches. 
It is the constraints on the immunogenicity and packaging 
capacity of the delivery modality.(81) Specificity of 
genome-editing reagents is paramount in therapeutics, as 
Figure 3. Common DNA targeting platforms for genome editing.(59) (Adapted with permission from American Society of Gene & Cell 
Therapy).
off-target mutations could lead to unintended side-effects. 
The inherent specificity of a given enzyme (independent of 
the target choice and its relative abundance of near-cognate 
matches in the genome) is dictated by both the DNA-
binding specificity of enzyme and the catalytic mechanism 
employed to introduce the DNA break.(81)
 A number of factors contribute to the absolute 
efficiency of a given gene-editing procedure, but most 
paramount is the quality of the nuclease. Considerations and 
observations for the overall editing rate, the number of edits 
that can be made simultaneously, and how editing outcome 
can potentially be influenced by the unique biochemistry 
of the different platforms. In addition to the quality and 
attributes of the nuclease, efficiency of editing can depend 
on several platform independent variables including the 
cell type (75), cell cycle (82), epigenetics at the target site 
(83,84) and delivery kinetics.
 We  still  facing  some  tricky  challenges   on   the 
technological side, about how to guarantee off-target 
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cleavage will not lead to mutations and compromise the 
expected benefits. Good progress is being made in both 
minimizing (85-88) and detecting (89) off-target effects, but 
the bar should be set very high before heritable modifications 
are pursued. We don’t have decent control over the types 
of modifications produced at the genomic target. After 
CRISPR/Cas (or ZFN or TALEN) cleavage, cellular repair 
continues to introduce local mutations or copy sequences 
from a homologous donor DNA. The second process was 
more covetable for most therapeutic applications, but the 
former typically dominates and must be minimized. After 
directing most of the current research to solve this issue, no 
effective approach has yet arrived. Any effective alternatives 
in current practices, particularly pre-implantation screening 
should be pointed out, and on the clinical side we also 
need to identify conditions as reasonable candidates for 
germline treatment.(90) These alternatives have their own 
drawbacks, both practical and ethical. It seems possible that 
germline gene correction may ultimately be suggested as 
an alternative to such procedures, once technical standards 
have been met.(91)
 Emerging gene-editing technologies are nearing 
a revolutionary phase in genetic medicine: accurately 
modifying or repairing causal genetic defects. Nowadays, 
these can carry out via programmable rare-cutting 
endonucleases,  generate  a  targeted  DNA  breaks,  involving 
any manipulation on DNA sequence, such as knocking 
out a deleterious gene, introducing a particular mutation, 
or directly repairing a deformed sequence by site-specific 
recombination,  then  engage  and exploit  endogenous 
DNA repair  pathways  to  deliver  site-specific  genetic 
changes.(81)
CRISPR-Cas 9: A Genome Engineering Tool
Few discoveries transform a discipline overnight, but 
biologists these days can manipulate cells in ways 
impossible  before,  thanks  to  a peculiar form of 
prokaryotic adaptive immunity mediated by CRISPR. 
Many delicate studies performed and make clear how 
these immune systems  function in bacteria and convince 
researchers about the technological potential of Cas9, 
an RNA-guided DNA  cleaving enzyme, in genome 
engineering.(92) Precise genome engineering in live cells at 
any locus promises to facilitate basic research and to enable 
personalized medicine. In particular, the latest development 
of the CRISPR-Cas9 system into a versatile and easy-to-
use editing tool (43) has been  celebrated  as  a  scientific 
breakthrough  in  the  field. As  genome  engineering  is 
adapted  to  clinical applications, a high level of precision, 
especially the avoidance of editing at  sites  other than the 
intended target, will be indispensable.(93)
Figure 4. Classes of designer nucleases and gene-editing outcomes. Targeted DSB can be induced using ZFNs, TALENs, or CRISPR/
Cas9. DNA breaks are repaired via endogenous repair pathways such as NHEJ and HR.(58) (Adapted with permission from American 
Society of Gene & Cell Therapy).
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chronic myelogenous leukemia, or induced pluripotent 
stem cells (iPSC) (17,18,101), as well as in mouse cells 
(17). The expected alterations in the target DNA were 
detected, indicating that site-specific DSBs by RNA-guided 
Cas9 had stimulated gene editing by non-homologous end 
joining repair or gene replacement by HDR. Targeting 
with multiple sgRNAs, also  referred  to  as  multiplexing, 
was successfully achieved.(17,18) RNA-programmable 
Streptococcus pyogenes Cas9-mediated editing has now 
been applied to various human cells and embryonic stem 
cells.(1,49,98,102-105). Although direct comparisons can 
be inconvenient to assess because of differences in target 
sites and protein expression levels, some analyses display 
that CRISPR-Cas9-mediated editing efficiencies can reach 
80% or more depending on the target, which is as  high  as 
or  higher  than  the  levels  observed  using  ZFNs  or 
TALENs.(104,106)
 Detailed   characterization   of   the  Cas9-guide 
complex  and  its  interference  mechanism  in   the   past 
(38,107)  has led  to  a  revolution  of  CRISPR-based 
genetic  engineering (108,109). The revolution includes 
directed recombination in bacteria (110,111), transcriptional 
activation and repression of synthetic regulons (112,113) and 
genome editing in eukaryotic cells, ranging from yeast to 
plant and from zebrafish to human (114). In addition for the 
directed silencing of the gene expression alternative system, 
we may also use RNA targeting by type III-B systems, as well 
as by Cas9. In terms of applications of CRISPR-associated 
nucleases in general, and Cas9 in particular, the sky seems 
to be the limit. Many improvements could be endeavor 
such as lowering the stringency of its PAM dependence and 
reducing its off-target cleavage. It’s crucial to also improve 
our understanding of the fundamental details of CRISPR-
Cas structure and function to optimize further expansion of 
CRISPR-Cas system applicability.(115)
 The significant advantages of the CRISPR/Cas system 
versus ZFNs and TALENs are as follows: (1)   a single 
protein is required, and it is always the same, no protein 
engineering is needed; (2) targeting depends on base pairing, 
so sgRNA design requires only knowledge of the Watson-
Crick rules; (3) new sgRNAs are very easily produced, (4)
because of advantages 1-3, it is feasible to attack multiple 
targets simultaneously with mixed sgRNAs.(74)
 The epigenome is a layer of regulatory information 
superimposed on the genome. It’s involved in the positions, 
compositions, and modifications of nucleosomes as well 
as modifications of DNA bases.(116) The epigenetics 
 The CRISPR-Cas system is widely found in bacterial 
and archaeal genomes as a defense mechanism against 
invading viruses and plasmids.(30,47,94-97) To target 
DNA, the type II CRISPR-Cas system from Streptococcus 
pyogenes depend on one protein, which is the nuclease 
Cas9, and two noncoding RNAs, namely crRNA and 
tracrRNA, which further can be fused into one single guide 
RNA (sgRNA). The Cas9/sgRNA complex binds double-
stranded DNA sequences which consist of a sequence 
match to the first 17-20 nucleotides of the sgRNA if the 
target sequence is followed by a PAM (Figure 5). After 
the two independent nuclease domains in Cas9 bound, 
they will each cleave one of the DNA strands three bases 
upstream of the PAM, and leaving a blunt end DNA DSB. 
DSBs can be repaired mainly through either NHEJ pathway 
or HDR. NHEJ typically leads to short indels near the 
cutting site, whilst HDR can be used to introduce specific 
sequences into the cutting site, if exogenous template 
DNA is available. This finding bricked the way of the Cas9 
application as a genome-engineering tool in other species. 
In this review, we only focus on target specificity of the 
CRISPR-Cas9 system, so for further discussion, we refer 
readers to other excellent articles as follows: (1,98-100). 
 Following the 2012 publication of Jinek, et al., three 
studies in  January 2013 illustrated  that CRISPR-Cas9 
represents  an  efficient  tool  to refine the  genomes of 
human cells.(17,18,43,101) The “humanized” versions of 
Streptococcus pyogenes Cas9 (17,18,101) and Streptococcus 
thermophilus  Cas9  (17)  were  coexpressed with custom-
designed sgRNAs (17,18,101) or with tracrRNA coexpressed 
with custom-designed crRNAs in human embryonic kidney, 
Figure 5. The CRISPR-Cas9 system. The sgRNA (purple) 
targets the Cas9 protein to genomic sites containing sequences 
complementary to the 5' end of the sgRNA. The target DNA 
sequence needs to be followed by a PAM.(100) (Adapted with 
permission from Higher Education Press and Springer-Verlag 
Berlin Heidelberg).
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 In the year of 2012, Cas9, programmed initial 
demonstration to cut various DNA sites in vitro, was 
published in a flurry of papers in the next year, suggested 
that this platform could efficiently function in various 
cells and organisms.(43) Initial proof-of-principle studies 
displayed that Cas9 could be targeted to endogenous genes 
in bacteria (110), cultured altered human cancer cell lines 
and human pluripotent stem cells in culture (17,18,101,121), 
also in a whole organism, the zebrafish (106). Subsequently, 
Cas9 has been used to refine genes in yeast (124), tobacco 
(125,126), thale cress (127), rice (127,128), wheat (127), 
sorghum (129), mice (130,131), rats (132), rabbits (133), 
frogs (134), fruit flies (135,136), silkworms (137) and 
roundworms (138).
 Here we highlight a few examples that illustrate 
the power of the technology. The first instance is the 
precise reproduction of tumor-associated chromosomal 
translocations that come about during carcinogenesis 
through an illegitimate non-homologous joining of two 
chromosomes. The ability of CRISPR-Cas9 to introduce 
DSBs  at  defined  positions  has  made  it  possible  to generate 
human cell lines and primary cells bearing chromosomal 
translations resembling those described in cancers  such  as 
lung cancer (137), acute myeloid leukemia, and Ewing’s 
sarcoma (138,139) (Figure 6). An improved method to 
generate liver cancer or myeloid malignancy models in 
mice facilitated by CRISPR-Cas9 was recently reported 
(140,141). CRISPR-Cas9 thus provides a robust technology 
for studying genomic rearrangements and the development 
and progression of cancers or other diseases.(19)
 Cas9 has already been widely used as a research 
tool, but the research expanded excitingly to develop Cas9 
as a therapeutic technology for treating genetic disorders. 
Monogenic recessive disorder due to loss-of-function 
mutations (such as cystic fibrosis, sickle-cell anemia, or 
Duchenne muscular dystrophy) will be a prospect case 
to be corrected causatively by Cas9. This has numbers of 
advantages over traditional methods of gene augmentation 
which transfer functional genetic copies trough viral 
vector-mediated overexpression-particularly that the 
newly functional gene is expressed in its natural context. 
For disorders with haplosufficient affected genes (such as 
transthyretin-related hereditary amyloidosis or dominant 
forms of retinitis pigmentosum), Therapeutic benefit 
possibly achieved by using NHEJ to inactivate the mutated 
allele.
 In addition to repairing mutations underlying inherited 
disorders, Cas9-mediated genome editing could also use 
to combat non-genetic or complex diseases by acquaint 
community has done a major ongoing effort that has 
already yielded millions of putative regulatory elements 
to map the epigenomic components genome-wide in many 
cell types. Recent reports in Nature Biotechnology by 
Hilton, et al., and in Nature Methods by Kearns, et al., 
have now addressed this need with an epigenome editing 
technology based on CRISPR-Cas9.(116-118) The studies 
that combining CRISPR-Cas9 ability in directing effectors 
to specific genomic sites with well-characterized, histone-
modifying domains functionally characterized the chromatin 
states of specific genomic elements and show the robust, 
specific transcriptional outcomes of histone modifications 
modulation.(119) The outcome of those studies suggest that 
using CRISPR-Cas9 for targeted epigenome editing was 
very  promising to be a simple but powerful method for 
probing  the  effects  of  histone  modifications  at  specific 
loci.
CRISPR-Cas 9 Applications
The Human Genome Project has earned a fairly complete 
catalog of cellular components, and a major goal is moving 
forward will be to classify all genetic elements involved 
in normal biological processes and disease.(120) With 
advances in gene editing enabled by the CRISPR-Cas 
system (17,18,43,121), it is no longer quixotic to seek a 
comprehensive  picture  of  cellular  circuitry  for  human 
cells (122).
 Journeyed from dreams about treating inherited 
disorders, gene therapy now encircled a wide range of 
strategies, started from the assumption that monogenic 
diseases would be the easiest to target. Classically, this 
therapy focused on enhancing endogenous DNA gene 
expression. These approaches rely on variety of viral vectors 
to transfer functional genes, adjusted to the virus intrinsic 
ability to effectively transduce in human cells.
 Thus, gene editing grows further on a thought about 
utilizing targeted disruption, insertion, excision and 
correction in both ex vivo and in vivo settings to permanently 
modify a genomic sequence of interest. Yet we foresee these 
advances to revolutionize larger without ignoring the safety 
concerns, modification efficacy and gene-editing tools 
to target cell types.(123) CRISPR-Cas9 nuclease system 
raises the hopes for a robust and precise modifying genomic 
sequences, make it possible to study of gene function at 
nucleotide resolution. To find a permanent way of correcting 
genetic mutation will rise an important advance in future 
therapy.(50)
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Figure 6. The Cas9 enzyme generates 
breaks in double-stranded DNA by 
using its two catalytic centers (blades) 
to cleave each strand of a DNA target 
site (yellow) beside a PAM sequence 
(red) and matching the 20-nucleotide 
sequence (orange) of the sgRNA).(19) 
(Adapted with permission from American 
Association for the Advancement of 
Science).
protective mutations in somatic tissues. For example, 
NHEJ-mediated inactivation of the C-C chemokine receptor 
type 5 (CCR5) in lymphocytes (142) may be a feasible 
strategy for circumventing HIV infection, while deletion of 
protein convertase subtilisin/kexin type 9 (PCSK9) (143) or 
angiopoietin (144) may provide therapeutic effects against 
statin-resistant hypercholesterolemia or hyperlipidemia. The 
unique advantage of this method rather than using sgRNA-
mediated protein knockdown is the ability to achieve 
permanent therapeutic benefit in one-time treatment. Of 
course every gene therapies proposed therapeutic use must 
count the favorable benefit-risk ratio.(1)
 The ability to manipulate any genomic sequence by 
gene editing has created diverse opportunities to treating 
many different diseases and disorders (Figure 7). We will 
discuss the major categories of disease indications that have 
been pursued in preclinical models, as well as highlight 
the ongoing or planned clinical trials using gene-editing 
strategies. Gene editing applied most straightforward ex 
vivo in gene knocking out for autologous cell therapy using 
the relatively efficient NHEJ mechanism, where somatic 
cells can be isolated, modified and delivered back to the 
patient. By this method, viral infection or replication can be 
prevented. Hence, the most advanced gene-editing strategy 
to date is the ex vivo modification of T-cells to knock out 
the CCR5 co-receptor used for primary HIV infection. The 
initiative study showed that in mice engrafted with T-cells in 
which the CCR5 gene had been knocked out by ZFNs, the 
viral loads decreased and cluster of differentiation (CD)4+ 
T-cell counts increased.(145)
 Beyond addressing HIV infection, all of the gene-
editing platforms have also been applied to various other 
viral pathogens (146), including hepatitis B virus (147-154), 
herpes simplex virus (155-157), and human papillomavirus 
(158). Viral genomes will be removed by degradation 
following nuclease cleavage and by targeting crucial genes 
needed for genome stability, maintenance, and replication.
 Cancer immunotherapy has been largely recognized as 
one of the biggest advances in biomedical research in recent 
years.(159) In particular, adoptive T-cell immunotherapy, 
in which autologous T-cells are designed to attack cancer 
antigens ex vivo and transferred back to the patient, has 
been impressively successful at treating some cases of 
lymphoma, leukemia, and melanoma.(160) Undeterred 
with those successes and promising ongoing clinical trial, 
gene editing could even more improve the potency of 
T-cell immunotherapy, as showed by many studies focused 
on knocking out the endogenous T-cell receptors with 
engineered nucleases.(161-164)
 Similarly, the successful of CD34+ hematopoietic 
stem  cell (HSC)  gene  editing  and  human  pluripotent 
cells capable of differentiating into erythroid progenitors 
has opened new options for treating other hematologic 
disorders, including treating specific E6V point mutation in 
the β-globin gene account for sickle cell disease, and other 
types of mutations to β-globin as the cause of β-thalassemia. 
Cas9 enzyme
10
The Indonesian Biomedical Journal, Vol.9, No.1, April 2017, p.1-16 Print ISSN: 2085-3297, Online ISSN: 2355-9179
Figure 7. Diversity of targets for therapeutic 
genome editing.(59) (Adapted with permission 
from American Society of Gene & Cell Therapy).
These globin mutations have been corrected by gene 
editing both in human iPSC that can be differentiated into 
functional erythrocytes (164-167) and directly in CD34+ 
HSCs.(168) Similar approaches have been developed for 
targeted integration  of therapeutic transgenes into safe 
harbor sites in human iPSCs for α-thalassemia (169) and 
Fanconi anemia (170).
 In applications to the human therapy, we need to 
make sure that the treatment will cure the one intentionally 
addressed without causing another unexpected condition. 
Auspiciously  that we  are  able  to  direct  subtle changes 
to  the  endogenous  target,  so  dangers  inherent  in  earlier 
methods   for  delivery  of  therapeutic  genes  could  be 
avoided.(171)
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proceed (with germline genetic manipulations) without 
resolution of safety issues and broad social consensus on 
application.’’(175)
 Although it was very possible to bring CRISPR-Cas-9 
to modify human germline, we have to consider that patient 
safety is paramount among the arguments against modifying 
the human germline (egg and sperm cells), because we can 
never be assured if the mosaic embryo created, its germline 
may carry the genetic alteration or not. Philosophically or 
ethically justifiable applications for this technology are 
moot until it becomes possible to prove safe outcomes and 
gain reproducible data over multiple generations. Due to 
safety and serious ethical reasons, around 40 countries until 
today, discourage or even ban germline modifications in 
human. Some countries indeed prohibited it a decade before 
the technical feasibility was confirmed in rats in the year 
2009.(71,90)
In human and non-human modifying, genome engineering 
technology didn’t offer lateral potencies. While in humans 
this technology preferred directed for curing a genetic 
disease, in other organisms, it present methods to reshape the 
biosphere for the advantage of the environment and human 
societies. However, we still do not know the unknown risks 
to human health and well-being yet.(172)
 The CRIPSR-Cas9 system is quite simple that allows 
any researcher with knowledge of biology molecular to 
modify genome, and conduct a previously difficult or 
impossible study as feasible. For example, a study on 
CRISPR-Cas9 to correct genetic defects in whole animals 
by an introduction of DNA sequence, such as replacing a 
mutated gene underlying liver-based metabolic disease 
in a mouse model.(173) The technique also enables DNA 
sequence changes in pluripotent embryonic stem cells (18) 
which can then be cultured to produce specific tissues, such 
as cardiomyocytes or neurons (174). Those basic researches 
will lay a frame of the foundation for real strategies to cure 
human disease. The ability of CRISPR-Cas9 to precisely 
replicate the genetic basis for human diseases in model 
organisms can be utilized to lead an unprecedented insight 
into previously enigmatic disorders.
 CRISPR-Cas9 technology, as well as other genome 
engineering methods, can be used to alter the DNA in the 
nuclei of reproductive cells which transmit information 
from one generation to the next (an organism’s “germline”). 
Thus, it is now possible to carry out genome modification 
in fertilized animal eggs or embryos, thereby shifting the 
genetic makeup of every differentiated cell in an organism 
and so ensuring that the alterations will be passed on to the 
organism’s progeny. It was also not impossible to apply 
this simple and widely available to set changes in human 
germline.(172)
 Early this year, about a month after the National 
Academy of Sciences (NAS) International Summit on 
Human Gene Editing, Stafford Academy for Technology 
(STAT) and the Harvard School of Public Health conducted 
a poll of adults in the US on gene editing. Their main 
finding was that an overwhelming majority of Americans 
(83%) believe it should be illegal to use gene editing to 
‘‘improve the intelligence or physical characteristics’’ of 
unborn babies. The summit stated a consensus, not a new 
law but did conclude that it would be ‘‘irresponsible to 
Ethical Implications of Human Germline Genome Editing
The story of how a mysterious prokaryotic viral defense 
system turn into one of the most powerful and versatile 
platforms for engineering biology irradiate the importance 
of basic science research. Just as recombinant DNA 
technology benefited from the basic investigation of the 
restriction enzymes which are central to warfare between 
phage and bacteria, the latest generation of Cas9-based 
genome engineering tools are also based on components 
from the microbial antiphage defense system. It is likely 
that the future solutions for efficient and precise gene 
modification will be found in as of yet unexplored corners 
of the rich biological diversity of nature.
 At last, by understanding the current studies of 
CRISPR application in creating tissue-based treatments 
for cancer and other currently untreatable diseases, every 
scientists’ dream about genetic manipulation is getting 
closer. Charpentier described its capabilities as “mind-
blowing.” For better or worse, the simple truth is, we all 
now live in CRISPR’s world, and what next this method will 
grow, the sky is the limit.
Conclusion
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